BlueBird's rare blood disorder drug gets breakthrough therapy status

February 2, 2015 1:15 PM

14 0

(Reuters) - The U.S. Food and Drug Administration has designated BlueBird Bio Inc's blood disorder drug a breakthrough therapy, speeding up the treatment's development process.

Breakthrough therapy designation is based on initial trial data and granted to drugs with the potential to treat serious diseases better than existing therapies.

Read more

To category page